Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CAMRELIZUMAB: 429 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
429
Total FAERS Reports
55 (12.8%)
Deaths Reported
136
Hospitalizations
429
As Primary/Secondary Suspect
39
Life-Threatening
5
Disabilities

First Report: 20171025 · Latest Report: 20250625

What Are the Most Common CAMRELIZUMAB Side Effects?

#1 Most Reported
Myelosuppression
70 reports (16.3%)
#2 Most Reported
Nausea
60 reports (14.0%)
#3 Most Reported
Fatigue
60 reports (14.0%)

All CAMRELIZUMAB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Myelosuppression 70 16.3% 4 29
Fatigue 60 14.0% 13 3
Nausea 60 14.0% 11 2
Vomiting 59 13.8% 11 3
Diarrhoea 54 12.6% 5 6
Anaemia 53 12.4% 11 4
Hypothyroidism 53 12.4% 7 2
Off label use 52 12.1% 15 9
Rash 50 11.7% 6 1
Thrombocytopenia 46 10.7% 6 5
Reactive capillary endothelial proliferation 41 9.6% 12 5
Therapy partial responder 38 8.9% 0 4
Leukopenia 37 8.6% 9 3
Pyrexia 37 8.6% 5 5
Alanine aminotransferase increased 33 7.7% 4 1
Pneumonia 33 7.7% 11 7
Hypertension 31 7.2% 2 2
Neutropenia 31 7.2% 4 1
Aspartate aminotransferase increased 30 7.0% 4 2
Decreased appetite 30 7.0% 4 4

Who Reports CAMRELIZUMAB Side Effects? Age & Gender Data

Gender: 44.6% female, 55.4% male. Average age: 54.7 years. Most reports from: CN. View detailed demographics →

Is CAMRELIZUMAB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2017 1 0 1
2018 2 0 2
2019 9 0 7
2020 19 3 12
2021 64 4 32
2022 42 2 29
2023 30 2 17
2024 22 2 10
2025 10 0 7

View full timeline →

What Is CAMRELIZUMAB Used For?

IndicationReports
Hepatocellular carcinoma 62
Hepatic cancer 36
Non-small cell lung cancer 25
Tumour thrombosis 17
Squamous cell carcinoma of the hypopharynx 16
Oesophageal squamous cell carcinoma 15
Lung neoplasm malignant 14
Lung adenocarcinoma 13
Gastric cancer 12
Neoplasm malignant 9

CAMRELIZUMAB vs Alternatives: Which Is Safer?

CAMRELIZUMAB vs CANAGLIFLOZIN CAMRELIZUMAB vs CANAGLIFLOZIN\METFORMIN CAMRELIZUMAB vs CANAKINUMAB CAMRELIZUMAB vs CANDESARTAN CAMRELIZUMAB vs CANDESARTAN CILEXETIL CAMRELIZUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE CAMRELIZUMAB vs CANGRELOR CAMRELIZUMAB vs CANIS LUPUS FAMILIARIS SKIN CAMRELIZUMAB vs CANNABIDIOL CAMRELIZUMAB vs CANNABIDIOL\HERBALS

Official FDA Label for CAMRELIZUMAB

Official prescribing information from the FDA-approved drug label.